MYC and colorectal carcinoma: A carboxamide-substituted benzhydryl amine, CBA-1, has been developed that acts as a KDM3A/3B inhibitor (mostly inhibiting KDM3A) and selectively induces elevated levels of H3K9me2, which in turn inhibits the Wnt targets (Auxin2, c-Myc, and Cyclin B1) and curtails in vitro CRC cell proliferation [72].